Synthego, a Redwood City, CA-based provider of genome engineering solutions, raised $41m in Series B financing.
The round was led by 8VC, with participation from Jerry Yang’s AME Cloud Ventures, Elements Capital, OS Fund, Alexandria Equities, ZhenFund, as well as CRISPR pioneer Jennifer Doudna and prominent researcher Jamie H Doudna Cate as well as previous investors Founders Fund, co-founded by Peter Thiel, Menlo Ventures, WI Harper Group, and Max Levchin’s SciFi VC.
The company, which has raised a total of $50m to date, intends to use the funds for growth of commercial operations, international expansion, and introduction of new products.
Founded in 2012 and led by CEO Paul Dabrowski, Synthego provides CRISPRevolution, a portfolio of synthetic RNA designed for CRISPR genome editing and research that aim to accelerate discovery in applications such as therapeutics, diagnostics, stem cell research and synthetic biology by removing guesswork from experimental workflows.
Customers include institutions in over 30 countries around the world and 9 of the top 10 global biology universities.